$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-K Financial Statement

#000104847720000009 Filed on February 27, 2020

Income Statement

Concept	2018 Q4	2017 Q4	2017
Revenue	$353.2M	$358.3M	$1.314B
YoY Change	-1.42%	19.39%	18.31%
Cost Of Revenue	$75.00M	$76.00M	$241.8M
YoY Change	-1.32%	18.56%	15.36%
Gross Profit	$278.2M	$282.3M	$1.072B
YoY Change	-1.45%	19.67%	18.15%
Gross Profit Margin	78.77%	78.79%	81.59%
Selling, General & Admin	$168.7M	$161.4M	$554.3M
YoY Change	4.52%	9.72%	17.2%
% of Gross Profit	60.64%	57.17%	51.72%
Research & Development	$175.4M	$168.6M	$610.8M
YoY Change	4.03%	-3.77%	-7.73%
% of Gross Profit	63.05%	59.72%	56.98%
Depreciation & Amortization	$24.70M	$28.70M	$87.86M
YoY Change	-13.94%	42.79%	-9.34%
% of Gross Profit	8.88%	10.17%	8.2%
Operating Expenses	$351.7M	$343.6M	$1.165B
YoY Change	2.36%	4.18%	0.0%
Operating Profit	-$73.50M	-$61.30M	-$14.70M
YoY Change	19.9%	-34.72%	-94.3%
Interest Expense	$3.200M	-$12.80M	$42.71M
YoY Change	-125.0%	357.14%	8.12%
% of Operating Profit
Other Income/Expense, Net	-$3.100M	$3.700M	$8.000M
YoY Change	-183.78%	-15.91%	63.27%
Pretax Income	-$43.30M	$54.60M	-$35.88M
YoY Change	-179.3%	-159.22%	-95.68%
Income Tax	-$44.30M	$63.70M	$81.17M
% Of Pretax Income		116.67%
Net Earnings	-$3.700M	-$51.40M	-$117.0M
YoY Change	-92.8%	-34.69%	-81.43%
Net Earnings / Revenue	-1.05%	-14.35%	-8.91%
Basic Earnings Per Share			-$0.67
Diluted Earnings Per Share	-$20.80K	-$292.9K	-$0.67
COMMON SHARES
Basic Shares Outstanding			174.4M shares
Diluted Shares Outstanding			174.4M shares

Balance Sheet

Concept	2018 Q4	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.084B	$1.396B	$1.396B
YoY Change	-22.33%	76.77%	76.78%
Cash & Equivalents	$494.0M	$598.0M	$598.0M
Short-Term Investments	$590.3M	$797.9M	$797.9M
Other Short-Term Assets	$98.40M	$74.04M	$74.00M
YoY Change	32.91%	19.99%	19.94%
Inventory	$530.9M	$475.8M	$475.8M
Prepaid Expenses
Receivables	$342.6M	$261.4M	$261.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.056B	$2.207B	$2.207B
YoY Change	-6.84%	55.24%	55.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$948.7M	$896.7M	$896.7M
YoY Change	5.8%	12.26%	12.26%
Goodwill	$197.0M
YoY Change
Intangibles	$491.8M
YoY Change
Long-Term Investments	$235.9M	$385.8M	$385.8M
YoY Change	-38.85%	-32.63%	-32.63%
Other Assets	$36.57M	$428.9M	$428.9M
YoY Change	-91.47%	-10.57%	-10.57%
Total Long-Term Assets	$2.371B	$2.426B	$2.426B
YoY Change	-2.27%	-6.76%	-6.76%
TOTAL ASSETS
Total Short-Term Assets	$2.056B	$2.207B	$2.207B
Total Long-Term Assets	$2.371B	$2.426B	$2.426B
Total Assets	$4.427B	$4.633B	$4.633B
YoY Change	-4.45%	15.15%	15.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$208.1M	$161.7M	$161.7M
YoY Change	28.7%	-18.54%	-18.54%
Accrued Expenses	$213.0M	$201.6M	$201.6M
YoY Change	5.65%	26.87%	26.87%
Deferred Revenue	$1.467M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$360.9M	$360.9M
YoY Change	-100.0%	1504.0%	1504.0%
Total Short-Term Liabilities	$523.2M	$816.5M	$816.5M
YoY Change	-35.92%	85.87%	85.86%
LONG-TERM LIABILITIES
Long-Term Debt	$830.4M	$813.5M	$813.5M
YoY Change	2.08%	23.11%	23.11%
Other Long-Term Liabilities	$58.65M	$194.4M	$194.4M
YoY Change	-69.83%	362.48%	23.59%
Total Long-Term Liabilities	$58.65M	$1.008B	$1.008B
YoY Change	-94.18%	2297.82%	23.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$523.2M	$816.5M	$816.5M
Total Long-Term Liabilities	$58.65M	$1.008B	$1.008B
Total Liabilities	$1.459B	$1.825B	$1.825B
YoY Change	-20.02%	45.1%	45.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.694B
YoY Change
Common Stock	$4.670B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.968B	$2.809B	$2.809B
YoY Change
Total Liabilities & Shareholders Equity	$4.427B	$4.633B	$4.633B
YoY Change	-4.45%	15.15%	15.15%

Cashflow Statement

Concept	2018 Q4	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	-$3.700M	-$51.40M	-$117.0M
YoY Change	-92.8%	-34.69%	-81.43%
Depreciation, Depletion And Amortization	$24.70M	$28.70M	$87.86M
YoY Change	-13.94%	42.79%	-9.34%
Cash From Operating Activities	$49.40M	$14.60M	-$8.757M
YoY Change	238.36%	-7400.0%	-96.16%
INVESTING ACTIVITIES
Capital Expenditures	-$42.10M	-$39.90M	$199.2M
YoY Change	5.51%	-22.67%	34.26%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	-$28.90M	$179.5M	$1.753M
YoY Change	-116.1%	-169.55%	151.15%
Cash From Investing Activities	-$70.90M	$139.5M	-$305.5M
YoY Change	-150.82%	-145.06%	-36.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-366.4M	13.10M	$507.1M
YoY Change	-2896.95%	-34.17%	-30.25%
NET CHANGE
Cash From Operating Activities	49.40M	14.60M	-$8.757M
Cash From Investing Activities	-70.90M	139.5M	-$305.5M
Cash From Financing Activities	-366.4M	13.10M	$507.1M
Net Change In Cash	-387.9M	167.2M	$189.7M
YoY Change	-332.0%	-157.68%	1146.05%
FREE CASH FLOW
Cash From Operating Activities	$49.40M	$14.60M	-$8.757M
Capital Expenditures	-$42.10M	-$39.90M	$199.2M
Free Cash Flow	$91.50M	$54.50M	-$208.0M
YoY Change	67.89%	6.03%	-44.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001048477
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	179838114	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	178252954	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	179838114	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	178252954	shares
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1640000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	413000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-272000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-1191000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax	0	USD
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	000-26727
CY2019	dei	Entity Registrant Name EntityRegistrantName	BioMarin Pharmaceutical Inc
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0397820
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	770 Lindaro Street
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	San Rafael
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94901
CY2019	dei	City Area Code CityAreaCode	415
CY2019	dei	Local Phone Number LocalPhoneNumber	506-6700
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $.001
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Trading Symbol TradingSymbol	BMRN
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	8100000000	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	179925602	shares
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	179925602	shares
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	437446000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493982000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	316361000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	590326000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	377404000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	342633000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	680275000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	530871000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	130657000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	98403000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1942143000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2056215000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	411978000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	235864000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1010868000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	948682000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	456580000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	491808000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197039000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	549422000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	460952000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122009000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36568000	USD
CY2019Q4	us-gaap	Assets Assets	4690039000	USD
CY2018Q4	us-gaap	Assets Assets	4427128000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	570621000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	437290000	USD
CY2019Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	361882000	USD
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	85951000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	932503000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	523241000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	486238000	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	830417000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	50793000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	46883000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98124000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58647000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1567658000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	1459188000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	180000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	178000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4832707000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4669926000	USD
CY2019Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	9961000	USD
CY2018Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	13301000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	20164000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5271000	USD
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1291000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1720709000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1694134000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3122381000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2967940000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4690039000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4427128000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1704048000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1491212000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1313646000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	359466000	USD
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	315264000	USD
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	241786000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	715007000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	696328000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	610753000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	680924000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	604353000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	554336000	USD
CY2019	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	74108000	USD
CY2018	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	48791000	USD
CY2017	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	46471000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	25000000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	50000000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	125000000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1804505000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	1614736000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	1328346000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-100457000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-123524000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-14700000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-587000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-553000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	22748000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	22831000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	14853000	USD
CY2019	us-gaap	Interest Expense InterestExpense	23460000	USD
CY2018	us-gaap	Interest Expense InterestExpense	43664000	USD
CY2017	us-gaap	Interest Expense InterestExpense	42707000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	6945000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2205000	USD
CY2017	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7970000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94811000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142705000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35875000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	81167000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	27433000	USD
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174427000	shares
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-117042000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	177061000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177268000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174427000	shares
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-117042000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5482000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1391000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-483000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	2061000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5482000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1391000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2544000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	25266000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	25386000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-38351000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	15853000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-2047000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-5113000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	9413000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-33238000	USD
CY2019	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	-2000	USD
CY2018	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	-6000	USD
CY2017	bmrn	Other Comprehensive Income Loss Other Net Of Tax OtherComprehensiveIncomeLossOtherNetOfTax	5000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14893000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	28818000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-35777000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8955000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48393000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-152819000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2967940000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2808663000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	2766275000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14893000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	28818000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-35777000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3122381000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2967940000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2808663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23848000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-77211000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-117042000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105300000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	95671000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	87861000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13960000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	31186000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	32300000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-358000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3077000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	159865000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	148819000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	140263000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	25000000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	50000000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	125000000	USD
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	714000	USD
CY2018	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	USD
CY2017	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	3252000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82760000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-68378000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	44464000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1025000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	17766000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6258000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5205000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	9296000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	10342000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1679000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2347000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5935000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37852000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54274000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25256000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	107554000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23747000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	96890000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	27008000	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	17767000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	20687000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8895000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	935000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2439000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	77089000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38389000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	45517000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	740211000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	993734000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	425960000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3128000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8914000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	5792000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48262000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20208000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8757000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	145026000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	144620000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	199219000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	632023000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	634753000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	655447000	USD
CY2019	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	25000000	USD
CY2018	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	50000000	USD
CY2017	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	125000000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18380000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	808000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	10000	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1753000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31026000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	264351000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305459000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31611000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	67488000	USD
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	60859000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	42680000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	35919000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	33507000	USD
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1894000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5087000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-74674000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-388007000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3231000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	481713000	USD
CY2019	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	374953000	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	26000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	58518000	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	44623000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	507145000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	902000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-598000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	9726000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	16676000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-56536000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-104046000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	189698000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493982000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	598028000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	408330000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	437446000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493982000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	598028000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	8552000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	11623000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	8544000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	23895000	USD
CY2019	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease	7589000	USD
CY2018	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease	-1206000	USD
CY2017	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease	-25786000	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	22477000	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS AND BUSINESS RISKS<div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s therapy portfolio consists of several commercial products and multiple clinical and preclinical product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks, including: the financial performance of its commercial products; the potential need for additional financing; the Company’s ability to successfully commercialize its approved products; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; the Company’s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.</span></div>
CY2019	us-gaap	Basis Of Accounting BasisOfAccounting	BASIS OF PRESENTATION<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">These Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Annual Reports on Form 10-K and include the accounts of BioMarin and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Certain amounts in these notes to the Company’s Consolidated Financial Statements have been reclassified to conform to the current period presentation. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that, other than the event discussed in Note 22 to these Consolidated Financial Statements, there were no subsequent events or transactions that occurred subsequent to the balance sheet date and prior to the filing this Annual Report on Form 10-K that would require recognition or disclosure in the Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"> Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Amounts reported for 2019 were presented under ASC Topic 842, whereas prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">. See Notes 4 and 12 to these Consolidated Financial Statements for additional discussion of the adoption of ASC Topic 842 and required disclosures.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">On January 1, 2019, the Company adopted Accounting Standards Update (ASU) No. 2017-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> (ASU 2017-12), using the modified retrospective method as discussed in Note 3 - Significant Accounting Policies. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for 2019 were presented under ASU 2017-12, whereas prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. See Note 4 for additional discussion of the adoption and Note 11 to these Consolidated Financial Statements for additional disclosures required by ASU 2017-12.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates.</span></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates.</span></div>
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	80000	USD
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2019Q1	bmrn	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	55900000	USD
CY2019Q1	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	59000000.0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1161152000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4713000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1165785000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	437446000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	316361000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	411978000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1322661000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	497000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2986000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1320172000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493982000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	590326000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	235864000	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	491808000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	652734000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	307995000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	326359000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	652734000	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	634354000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	196154000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	142546000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	456580000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	456580000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	62887000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	61963000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	55036000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	130366000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	61939000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	61311000	USD
CY2019Q4	bmrn	Finite Lived Intangible Assets Amortization Not Commenced Net FiniteLivedIntangibleAssetsAmortizationNotCommencedNet	433502000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	326400000	USD
CY2017	us-gaap	Depreciation Depreciation	75800000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1559968000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1421317000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	549100000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	472635000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1010868000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	948682000	USD
CY2019	us-gaap	Depreciation Depreciation	89300000	USD
CY2018	us-gaap	Depreciation Depreciation	90400000	USD
CY2019	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	37500000	USD
CY2018	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	25200000	USD
CY2017	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	24100000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	74442000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	74616000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	349978000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	231064000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	255855000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	225191000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	680275000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	530871000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	240981000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	207620000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	192467000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	149937000	USD
CY2019Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	57163000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4178000	USD
CY2018Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	43116000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	10700000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	30797000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	19977000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13037000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1467000	USD
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	8395000	USD
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	7785000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	10448000	USD
CY2019Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6633000	USD
CY2018Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3210000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	570621000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	437290000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	23178000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	15941000	USD
CY2018Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	7831000	USD
CY2019Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	33592000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1804505000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	49045000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10389000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10019000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3705000	USD
CY2019Q4	bmrn	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	59434000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7451000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3249000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44092000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6708000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	61500000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	13724000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9081000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3090000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	12171000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8699000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2346000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	11045000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7748000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	1748000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour	9496000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5916000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive	5916000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	22027000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due After Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive	22027000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63490000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	10889000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	74379000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11947000	USD
CY2019Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	932000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	12879000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	51543000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	12549000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	9957000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	11198000	USD
CY2019Q4	bmrn	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	61500000	USD
CY2019	us-gaap	Lease Cost LeaseCost	16247000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	12200000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11400000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	12976000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	10574000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9993000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	27701000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	84991000	USD
CY2018Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	2100000	USD
CY2018Q4	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	500000	USD
CY2018Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	911348000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5087000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9772000	USD
CY2019Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	927518000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8183000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	628000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	3267000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	870000000.0	USD
CY2019Q4	us-gaap	Convertible Debt ConvertibleDebt	848120000	USD
CY2018Q4	us-gaap	Convertible Debt ConvertibleDebt	830417000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	28818000	USD
CY2019	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	32386000	USD
CY2019	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	15853000	USD
CY2018	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	27184000	USD
CY2018	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	-2047000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	413000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1640000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14893000	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1704048000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1491212000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1313646000	USD
CY2018Q4	us-gaap	Noncurrent Assets NoncurrentAssets	2099194000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	39700000	shares
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	20300000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	2270506000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	159865000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	148819000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	140263000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	183091000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	610250	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	94.45
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	20000000.0	USD
CY2017	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	16100000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7363609	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	63.06
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	567672	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	28.95
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	141952	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	82.24
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7264235	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	67.99
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	146700000	USD
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1258052	shares
CY2019Q4	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	89.49
CY2019	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P8Y6M
CY2019Q4	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue	447000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6006183	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	63.48
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	146253000	USD
CY2019Q4	us-gaap	Share Price SharePrice	84.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.84
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.40
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	36.07
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	32500000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	79900000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	77000000.0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	1200000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-182112000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-128700000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19461000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	87301000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-14005000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-16414000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-94811000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-142705000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-35875000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5127000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2660000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	29848000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1331000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	588000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2880000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5339000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4956000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3975000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11797000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2884000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-19055000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4690000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	36703000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-58311000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-72074000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12446000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5394000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-994000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	32336000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-318000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82760000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-68378000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	44464000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	81167000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	239000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19911000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-29968000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12556000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2784000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-276000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7282000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	43124000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	66451000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	33683000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5647000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-6843000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	-1804000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	-2361000	USD
CY2017	bmrn	Income Tax Rate Reconciliation Changes In Fair Value Of Contingent Consideration IncomeTaxRateReconciliationChangesInFairValueOfContingentConsideration	1099000	USD
CY2019	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	-52000	USD
CY2017	bmrn	Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 IncomeTaxRateReconciliationTaxCutsAndJobsActOf2017	42338000	USD
CY2018	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	6543000	USD
CY2017	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	30181000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 IncomeTaxRateReconciliationTaxCutsAndJobsActOf2017	0	USD
CY2018	bmrn	Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 IncomeTaxRateReconciliationTaxCutsAndJobsActOf2017	0	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-30639000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12583000	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	9403000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	8294000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	7440000	USD
CY2017	bmrn	Income Tax Rate Reconciliation Section162 Limitation IncomeTaxRateReconciliationSection162Limitation	9492000	USD
CY2019	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	12123000	USD
CY2018	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	8545000	USD
CY2017	bmrn	Income Tax Rate Reconciliation Tax Reserves IncomeTaxRateReconciliationTaxReserves	2262000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1132000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-423000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2940000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7827000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4521000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35132000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70963000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65494000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	81167000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32181000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42007000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	508560000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	466066000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	61807000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	55041000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	29413000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	18734000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	42873000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	35966000	USD
CY2019Q4	bmrn	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	11470000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6290000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	12859000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	575000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	278000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86197000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107928000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	606972000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	523023000	USD
CY2019Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	993000	USD
CY2018Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	1010000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1647000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6508000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	3003000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	4480000	USD
CY2019Q4	bmrn	Deferred Tax Liability Related To Convertible Notes DeferredTaxLiabilityRelatedToConvertibleNotes	2364000	USD
CY2018Q4	bmrn	Deferred Tax Liability Related To Convertible Notes DeferredTaxLiabilityRelatedToConvertibleNotes	5157000	USD
CY2019Q4	bmrn	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	10258000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	46642000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	44916000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	64907000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	62071000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	542065000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	460952000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	147445000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	113486000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	19287000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	30811000	USD
CY2019	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2016000	USD
CY2018	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	3148000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	168748000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	147445000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	167200000	USD
CY2019Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	31200000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23848000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77211000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-117042000	USD
CY2019	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	0	USD
CY2018	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	-710000	USD
CY2017	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	0	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23848000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-77921000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-117042000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	177061000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19965000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174427000	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	207000	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179039000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177268000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174427000	shares
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2019	bmrn	Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones	361300000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	50800000	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19156000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23611000	shares
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8800000	USD
CY2019	bmrn	Termination Of Collaborative Agreement TerminationOfCollaborativeAgreement	P90D
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	106200000	USD
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3000000.0	USD
CY2018Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	4900000	USD

Files In Submission

Name	View Source	Status
0001048477-20-000009-index-headers.html	Edgar Link	pending
0001048477-20-000009-index.html	Edgar Link	pending
0001048477-20-000009.txt	Edgar Link	pending
0001048477-20-000009-xbrl.zip	Edgar Link	pending
bmrn-20191231.htm	Edgar Link	pending
bmrn-20191231.xsd	Edgar Link	pending
bmrn-20191231xexx211.htm	Edgar Link	pending
bmrn-20191231xexx231.htm	Edgar Link	pending
bmrn-20191231xexx311.htm	Edgar Link	pending
bmrn-20191231xexx312.htm	Edgar Link	pending
bmrn-20191231xexx321.htm	Edgar Link	pending
bmrn-20191231xexx46.htm	Edgar Link	pending
bmrn-20191231_cal.xml	Edgar Link	unprocessable
bmrn-20191231_def.xml	Edgar Link	unprocessable
bmrn-20191231_g1.jpg	Edgar Link	pending
bmrn-20191231_htm.xml	Edgar Link	completed
bmrn-20191231_lab.xml	Edgar Link	unprocessable
bmrn-20191231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2018 Q4 Form 10-K Financial Statement

#000104847720000009 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2018 Q4 Form 10-K Financial Statement

#000104847720000009 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn